BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini E, Tiram G, Liubomirski Y, Satchi-Fainaro R. Immune-mediated approaches against COVID-19. Nat Nanotechnol 2020;15:630-45. [PMID: 32661375 DOI: 10.1038/s41565-020-0732-3] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 54.0] [Reference Citation Analysis]
Number Citing Articles
1 Mandal A, Mallik S, Mondal S, Subhadarshini S, Sadhukhan R, Ghoshal T, Mitra S, Manna M, Mandal S, Goswami DK. Diffusion-Induced Ingress of Angiotensin-Converting Enzyme 2 into the Charge Conducting Path of a Pentacene Channel for Efficient Detection of SARS-CoV-2 in Saliva Samples. ACS Sens 2022. [PMID: 36129125 DOI: 10.1021/acssensors.2c01287] [Reference Citation Analysis]
2 Alakus TB, Turkoglu I. Prediction of viral-host interactions of COVID-19 by computational methods. Chemometr Intell Lab Syst 2022;:104622. [PMID: 35879939 DOI: 10.1016/j.chemolab.2022.104622] [Reference Citation Analysis]
3 Rastogi A, Singh A, Naik K, Mishra A, Chaudhary S, Manohar R, Singh Parmar A. A systemic review on liquid crystals, nanoformulations and its application for detection and treatment of SARS - CoV- 2 (COVID - 19). J Mol Liq 2022;362:119795. [PMID: 35832289 DOI: 10.1016/j.molliq.2022.119795] [Reference Citation Analysis]
4 Alfaro S, Acuña V, Ceriani R, Cavieres MF, Weinstein-oppenheimer CR, Campos-estrada C. Involvement of Inflammation and Its Resolution in Disease and Therapeutics. IJMS 2022;23:10719. [DOI: 10.3390/ijms231810719] [Reference Citation Analysis]
5 Balakrishna Pillai A, Mariappan V, JeanPierre AR, Rao SR. Restoration of vascular endothelial integrity by mesenchymal stromal/stem cells in debilitating virus diseases. Hum Cell 2022. [PMID: 36068397 DOI: 10.1007/s13577-022-00785-3] [Reference Citation Analysis]
6 Natesan Pushparaj P, Damiati LA, Denetiu I, Bakhashab S, Asif M, Hussain A, Ahmed S, Hamdard MH, Rasool M. Deciphering SARS CoV-2-associated pathways from RNA sequencing data of COVID-19-infected A549 cells and potential therapeutics using in silico methods. Medicine 2022;101:e29554. [DOI: 10.1097/md.0000000000029554] [Reference Citation Analysis]
7 Huang X, Kon E, Han X, Zhang X, Kong N, Mitchell MJ, Peer D, Tao W. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat Nanotechnol 2022. [PMID: 35982317 DOI: 10.1038/s41565-022-01174-5] [Reference Citation Analysis]
8 Averyanova M, Vishnyakova P, Yureneva S, Yakushevskaya O, Fatkhudinov T, Elchaninov A, Sukhikh G. Sex hormones and immune system: Menopausal hormone therapy in the context of COVID-19 pandemic. Front Immunol 2022;13:928171. [DOI: 10.3389/fimmu.2022.928171] [Reference Citation Analysis]
9 Smer A, Squires RW, Bonikowske AR, Allison TG, Mainville RN, Williams MA. Cardiac Complications of COVID-19 Infection and the Role of Physical Activity. J Cardiopulm Rehabil Prev 2022. [PMID: 35839441 DOI: 10.1097/HCR.0000000000000701] [Reference Citation Analysis]
10 Asif M, Amir M, Hussain A, Achakzai NM, Natesan Pushparaj P, Rasool M. Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review. Medicine (Baltimore) 2022;101:e29660. [PMID: 35777011 DOI: 10.1097/MD.0000000000029660] [Reference Citation Analysis]
11 Morajkar RV, Kumar AS, Kunkalekar RK, Vernekar AA. Advances in nanotechnology application in biosafety materials: a crucial response to COVID-19 pandemic. Biosaf Health 2022. [PMID: 35765656 DOI: 10.1016/j.bsheal.2022.06.001] [Reference Citation Analysis]
12 Muhar BK, Nehira J, Malhotra A, Kotchoni SO. The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses. J Pharm Pract 2022;:8971900221097248. [PMID: 35723017 DOI: 10.1177/08971900221097248] [Reference Citation Analysis]
13 Msungu SD, Mushongi AA, Venkataramana PB, Mbega ER. A review on the trends of maize biofortification in alleviating hidden hunger in sub-Sahara Africa. Scientia Horticulturae 2022;299:111029. [DOI: 10.1016/j.scienta.2022.111029] [Reference Citation Analysis]
14 Hassan J, Haigh C, Ahmed T, Uddin MJ, Das DB. Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges. Pharmaceutics 2022;14:1066. [DOI: 10.3390/pharmaceutics14051066] [Reference Citation Analysis]
15 Benedetto A, Kelley EG. Absorption of the [bmim][Cl] Ionic Liquid in DMPC Lipid Bilayers across Their Gel, Ripple, and Fluid Phases. J Phys Chem B 2022. [PMID: 35472281 DOI: 10.1021/acs.jpcb.2c00710] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Mobasheri L, Hossein Nasirpour M, Masoumi E, Foolady Azarnaminy A, Jafari M, Esmaeili S. SARS-CoV-2 triggering autoimmune diseases. Cytokine 2022. [DOI: 10.1016/j.cyto.2022.155873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
17 Firoz A, Talwar P. COVID-19 and Retinal Degenerative Diseases: Promising link “Kaempferol”. Current Opinion in Pharmacology 2022. [DOI: 10.1016/j.coph.2022.102231] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bregnocchi A, Jafari R, Momen G. Design strategies for antiviral coatings and surfaces: A review. Applied Surface Science Advances 2022;8:100224. [DOI: 10.1016/j.apsadv.2022.100224] [Reference Citation Analysis]
19 Rabiu Abubakar A, Ahmad R, Rowaiye AB, Rahman S, Iskandar K, Dutta S, Oli AN, Dhingra S, Tor MA, Etando A, Kumar S, Irfan M, Gowere M, Chowdhury K, Akter F, Jahan D, Schellack N, Haque M. Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. Life 2022;12:478. [DOI: 10.3390/life12040478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Banerjee S, Banerjee D, Singh A, Saharan VA. A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. AAPS PharmSciTech 2022;23:95. [PMID: 35314902 DOI: 10.1208/s12249-022-02247-3] [Reference Citation Analysis]
21 Zuo C, Zhu F, Meng Z, Ling Y, Zheng Y, Zhao X. Analyzing the COVID-19 vaccination behavior based on epidemic model with awareness-information. Infect Genet Evol 2022;98:105218. [PMID: 35066164 DOI: 10.1016/j.meegid.2022.105218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Dubey AK, Chaudhry SK, Singh HB, Gupta VK, Kaushik A. Perspectives on nano-nutraceuticals to manage pre and post COVID-19 infections. Biotechnol Rep (Amst) 2022;33:e00712. [PMID: 35186674 DOI: 10.1016/j.btre.2022.e00712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
23 Chen L, Qu J, Kalyani FS, Zhang Q, Fan L, Fang Y, Li Y, Xiang C. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-021-04096-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 El-Sayed EM, Ibrahim KS. Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19. Mol Biol Rep 2022. [PMID: 35169998 DOI: 10.1007/s11033-022-07226-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ljubimov VA, Ramesh A, Davani S, Danielpour M, Breunig JJ, Black KL. Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Adv Drug Deliv Rev 2022;181:114033. [PMID: 34808227 DOI: 10.1016/j.addr.2021.114033] [Reference Citation Analysis]
26 Mallakpour S, Behranvand V, Hussain CM. Worldwide fight against COVID-19 using nanotechnology, polymer science, and 3D printing technology. Polym Bull . [DOI: 10.1007/s00289-021-04006-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Mohammed SA, Shaaban EIA. Efficacious nanomedicine track toward combating COVID-19. Nanotechnology Reviews 2022;11:680-98. [DOI: 10.1515/ntrev-2022-0036] [Reference Citation Analysis]
28 Scussel R, Feuser PE, Luiz GP, Galvani NC, Fagundes MÍ, Gonçalves Dal-Bó A, Hermes de Araújo PH, Coelho EAF, Chávez-Olórtegui C, Machado-de-Ávila RA. Peptide-Integrated Superparamagnetic Nanoparticles for the Identification of Epitopes from SARS-CoV-2 Spike and Nucleocapsid Proteins. ACS Appl Nano Mater 2022;5:642-53. [PMID: 35098045 DOI: 10.1021/acsanm.1c03399] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chakraborty C, Sharma AR, Bhattacharya M, Zayed H, Lee SS. Understanding Gene Expression and Transcriptome Profiling of COVID-19: An Initiative Towards the Mapping of Protective Immunity Genes Against SARS-CoV-2 Infection. Front Immunol 2021;12:724936. [PMID: 34975833 DOI: 10.3389/fimmu.2021.724936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
30 Yu PC, Huang CH, Kuo CJ, Liang PH, Wang LH, Pan MY, Chang SY, Chao TL, Ieong SM, Fang JT, Huang HC, Juan HF. Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. Pharmaceutics 2022;14:176. [PMID: 35057070 DOI: 10.3390/pharmaceutics14010176] [Reference Citation Analysis]
31 Bharathi M, Sivamaruthi BS, Kesika P, Thangaleela S, Chaiyasut C. In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. Applied Sciences 2022;12:665. [DOI: 10.3390/app12020665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Feng T, Nie C, Peng P, Lu H, Wang T, Li P, Huang W. Nanoagent-based theranostic strategies against human coronaviruses. Nano Res 2022;:1-15. [PMID: 35003529 DOI: 10.1007/s12274-021-3949-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shen Q, Li J, Zhang Z, Guo S, Wang Q, An X, Chang H. COVID-19: systemic pathology and its implications for therapy. Int J Biol Sci 2022;18:386-408. [PMID: 34975340 DOI: 10.7150/ijbs.65911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
34 Alseoudy MM, Elgamal M, Abdelghany DA, Borg AM, El-mesery A, Elzeiny D, Hammad MO. Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.108929] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Chen J, Wang B, Caserto JS, Shariati K, Cao P, Pan Y, Xu Q, Ma M. Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold. Adv Healthc Mater 2022;11:e2101714. [PMID: 34755476 DOI: 10.1002/adhm.202101714] [Reference Citation Analysis]
36 Kalantari S, Sadeghzadeh-Bazargan A, Ebrahimi S, Yassin Z, Faiz SHR, Kabir A, Baghestani A, Mashayekhi F, Bokharaei-Salim F, Goodarzi A. The effect of influenza vaccine on severity of COVID-19 infection: An original study from Iran. Med J Islam Repub Iran 2021;35:114. [PMID: 34956960 DOI: 10.47176/mjiri.35.114] [Reference Citation Analysis]
37 Liu Y, Zhou X, Liu X, Jiang X. The immunology and immunotherapy for COVID-19. Expert Rev Mol Med 2021;23:e24. [PMID: 34915958 DOI: 10.1017/erm.2021.30] [Reference Citation Analysis]
38 Yap C, Ali A, Prabhakar A, Prabhakar A, Pal A, Lim YY, Kakodkar P. Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Ther Adv Vaccines Immunother 2021;9:25151355211059791. [PMID: 34870090 DOI: 10.1177/25151355211059791] [Reference Citation Analysis]
39 Spiering AE, de Vries TJ. Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19. Front Immunol 2021;12:756262. [PMID: 34858409 DOI: 10.3389/fimmu.2021.756262] [Reference Citation Analysis]
40 Ikewaki N, Raghavan K, Dedeepiya VD, Vaddi S, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJ. Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats. Clinical Immunology Communications 2021;1:29-34. [DOI: 10.1016/j.clicom.2021.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Islam F, Bibi S, Meem AFK, Islam MM, Rahaman MS, Bepary S, Rahman MM, Rahman MM, Elzaki A, Kajoak S, Osman H, ElSamani M, Khandaker MU, Idris AM, Emran TB. Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19. Int J Mol Sci 2021;22:12638. [PMID: 34884440 DOI: 10.3390/ijms222312638] [Reference Citation Analysis]
42 Brain D, Plant-Hately A, Heaton B, Arshad U, David C, Hedrich C, Owen A, Liptrott NJ. Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Adv Drug Deliv Rev 2021;178:113848. [PMID: 34182016 DOI: 10.1016/j.addr.2021.113848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
43 Othman SI, Nayel MA, Alwaele MA, Al Fassam H, Abu-Taweel GM, Altoom NG, Almalki AM, Allam AA, Alturki AM, El-Shabasy RM. Immunology and controlling of coronaviruses; the current enemy for humanity: A review. Int J Biol Macromol 2021:S0141-8130(21)02381-3. [PMID: 34732305 DOI: 10.1016/j.ijbiomac.2021.10.216] [Reference Citation Analysis]
44 Zamzami MA, Rabbani G, Ahmad A, Basalah AA, Al-Sabban WH, Nate Ahn S, Choudhry H. Carbon nanotube field-effect transistor (CNT-FET)-based biosensor for rapid detection of SARS-CoV-2 (COVID-19) surface spike protein S1. Bioelectrochemistry 2022;143:107982. [PMID: 34715586 DOI: 10.1016/j.bioelechem.2021.107982] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 28.0] [Reference Citation Analysis]
45 Talebian S, Rodrigues T, das Neves J, Sarmento B, Langer R, Conde J. Facts and Figures on Materials Science and Nanotechnology Progress and Investment. ACS Nano 2021;15:15940-52. [PMID: 34320802 DOI: 10.1021/acsnano.1c03992] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
46 Murugan C, Ramamoorthy S, Kuppuswamy G, Murugan RK, Sivalingam Y, Sundaramurthy A. COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. Int J Biol Macromol 2021:S0141-8130(21)02301-1. [PMID: 34710479 DOI: 10.1016/j.ijbiomac.2021.10.144] [Reference Citation Analysis]
47 Liu M, Li Z, Liu M, Zhu Y, Liu Y, Kuetche MWN, Wang J, Wang X, Liu X, Li X, Wang W, Guo X, Tao L. Association between temperature and COVID-19 transmission in 153 countries. Environ Sci Pollut Res Int 2021. [PMID: 34637125 DOI: 10.1007/s11356-021-16666-5] [Reference Citation Analysis]
48 Viana Invenção MDC, Melo ARDS, de Macêdo LS, da Costa Neves TSP, de Melo CML, Cordeiro MN, de Aragão Batista MV, de Freitas AC. Development of synthetic antigen vaccines for COVID-19. Hum Vaccin Immunother 2021;:1-16. [PMID: 34613880 DOI: 10.1080/21645515.2021.1974288] [Reference Citation Analysis]
49 Balkrishna A, Arya V, Rohela A, Kumar A, Verma R, Kumar D, Nepovimova E, Kuca K, Thakur N, Thakur N, Kumar P. Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines. Vaccines (Basel) 2021;9:1129. [PMID: 34696237 DOI: 10.3390/vaccines9101129] [Reference Citation Analysis]
50 Tiwari V, Kumar M, Tiwari A, Sahoo BM, Singh S, Kumar S, Saharan R. Current trends in diagnosis and treatment strategies of COVID-19 infection. Environ Sci Pollut Res Int 2021;28:64987-5013. [PMID: 34601675 DOI: 10.1007/s11356-021-16715-z] [Reference Citation Analysis]
51 Shah SM, Alsaab HO, Rawas-Qalaji MM, Uddin MN. A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems. Vaccines (Basel) 2021;9:1086. [PMID: 34696194 DOI: 10.3390/vaccines9101086] [Reference Citation Analysis]
52 Zieneldien T, Kim J, Cao J, Cao C. COVID-19 Vaccines: Current Conditions and Future Prospects. Biology (Basel) 2021;10:960. [PMID: 34681059 DOI: 10.3390/biology10100960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
53 Al-Wahaibi LH, Mostafa A, Mostafa YA, Abou-Ghadir OF, Abdelazeem AH, Gouda AM, Kutkat O, Abo Shama NM, Shehata M, Gomaa HAM, Abdelrahman MH, Mohamed FAM, Gu X, Ali MA, Trembleau L, Youssif BGM. Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease. Bioorg Chem 2021;116:105363. [PMID: 34555629 DOI: 10.1016/j.bioorg.2021.105363] [Reference Citation Analysis]
54 Farmani AR, Mahdavinezhad F, Scagnolari C, Kouhestani M, Mohammadi S, Ai J, Shoormeij MH, Rezaei N. An overview on tumor treating fields (TTFields) technology as a new potential subsidiary biophysical treatment for COVID-19. Drug Deliv Transl Res 2021. [PMID: 34542840 DOI: 10.1007/s13346-021-01067-5] [Reference Citation Analysis]
55 Thodi RC, Ibrahim JM, Surendran VA, Nair AS, Sukumaran ST. Rutaretin1'-(6″-sinapoylglucoside): promising inhibitor of COVID 19 mpro catalytic dyad from the leaves of Pittosporum dasycaulon miq (Pittosporaceae). J Biomol Struct Dyn 2021;:1-17. [PMID: 34528865 DOI: 10.1080/07391102.2021.1972841] [Reference Citation Analysis]
56 Wang L, Wang X, Yang F, Liu Y, Meng L, Pang Y, Zhang M, Chen F, Pan C, Lin S, Zhu X, Leong KW, Liu J. Systemic antiviral immunization by virus-mimicking nanoparticles-decorated erythrocytes. Nano Today 2021;40:101280. [PMID: 34512795 DOI: 10.1016/j.nantod.2021.101280] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Said MA, Khan DJO, Al-Blewi FF, Al-Kaff NS, Ali AA, Rezki N, Aouad MR, Hagar M. New 1,2,3-Triazole Scaffold Schiff Bases as Potential Anti-COVID-19: Design, Synthesis, DFT-Molecular Docking, and Cytotoxicity Aspects. Vaccines (Basel) 2021;9:1012. [PMID: 34579249 DOI: 10.3390/vaccines9091012] [Reference Citation Analysis]
58 Yayehrad AT, Siraj EA, Wondie GB, Alemie AA, Derseh MT, Ambaye AS. Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives. Int J Nanomedicine 2021;16:5713-43. [PMID: 34465991 DOI: 10.2147/IJN.S327334] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Barros MT, Veletic M, Kanada M, Pierobon M, Vainio S, Balasingham I, Balasubramaniam S. Molecular Communications in Viral Infections Research: Modeling, Experimental Data, and Future Directions. IEEE Trans Mol Biol Multiscale Commun 2021;7:121-41. [PMID: 35782714 DOI: 10.1109/TMBMC.2021.3071780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
60 Philips CA, Kakkar K, Joseph M, Yerol PK, Ahamed R, Rajesh S, Augustine P. Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care. J Clin Transl Hepatol 2021;9:576-86. [PMID: 34447688 DOI: 10.14218/JCTH.2020.00110] [Reference Citation Analysis]
61 Banerjee Y, Pantea Stoian A, Silva-Nunes J, Sonmez A, Rizvi AA, Janez A, Rizzo M. The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf 2021;20:1309-15. [PMID: 34424130 DOI: 10.1080/14740338.2021.1970744] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, Dong X, Zheng P. N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2. Elife 2021;10:e69091. [PMID: 34414884 DOI: 10.7554/eLife.69091] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
63 Manosso LM, Arent CO, Borba LA, Ceretta LB, Quevedo J, Réus GZ. Microbiota-Gut-Brain Communication in the SARS-CoV-2 Infection. Cells 2021;10:1993. [PMID: 34440767 DOI: 10.3390/cells10081993] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Rehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed Pharmacother 2021;142:112015. [PMID: 34388532 DOI: 10.1016/j.biopha.2021.112015] [Reference Citation Analysis]
65 Nasir AM, Awang N, Hubadillah SK, Jaafar J, Othman MHD, Wan Salleh WN, Ismail AF. A review on the potential of photocatalysis in combatting SARS-CoV-2 in wastewater. J Water Process Eng 2021;42:102111. [PMID: 35592059 DOI: 10.1016/j.jwpe.2021.102111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
66 Vale FF, Vítor JMB, Marques AT, Azevedo-Pereira JM, Anes E, Goncalves J. Origin, phylogeny, variability and epitope conservation of SARS-CoV-2 worldwide. Virus Res 2021;304:198526. [PMID: 34339772 DOI: 10.1016/j.virusres.2021.198526] [Reference Citation Analysis]
67 Qu Y, Wang X, Zhu Y, Wang W, Wang Y, Hu G, Liu C, Li J, Ren S, Xiao MZX, Liu Z, Wang C, Fu J, Zhang Y, Li P, Zhang R, Liang Q. ORF3a-Mediated Incomplete Autophagy Facilitates Severe Acute Respiratory Syndrome Coronavirus-2 Replication. Front Cell Dev Biol 2021;9:716208. [PMID: 34386498 DOI: 10.3389/fcell.2021.716208] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Nasrollahi F, Haghniaz R, Hosseini V, Davoodi E, Mahmoodi M, Karamikamkar S, Darabi MA, Zhu Y, Lee J, Diltemiz SE, Montazerian H, Sangabathuni S, Tavafoghi M, Jucaud V, Sun W, Kim HJ, Ahadian S, Khademhosseini A. Micro and Nanoscale Technologies for Diagnosis of Viral Infections. Small 2021;:e2100692. [PMID: 34310048 DOI: 10.1002/smll.202100692] [Reference Citation Analysis]
69 Gong F, Wei HX, Qi J, Ma H, Liu L, Weng J, Zheng X, Li Q, Zhao D, Fang H, Liu L, He H, Ma C, Han J, Sun A, Wang B, Jin T, Li B, Li B. Pulling-Force Spinning Top for Serum Separation Combined with Paper-Based Microfluidic Devices in COVID-19 ELISA Diagnosis. ACS Sens 2021;6:2709-19. [PMID: 34263598 DOI: 10.1021/acssensors.1c00773] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
70 Giardino G, Romano R, Coppola E, Cillo F, Borzachiello C, De Luca M, Palamaro L, Toriell E, Prencipe R, Cirillo E, Pignata C. SARS-CoV-2 infection in the immunodeficient host: necessary and dispensable immune pathways. J Allergy Clin Immunol Pract 2021:S2213-2198(21)00778-9. [PMID: 34273582 DOI: 10.1016/j.jaip.2021.06.045] [Reference Citation Analysis]
71 Singh L, Bajaj S, Gadewar M, Verma N, Ansari MN, Saeedan AS, Kaithwas G, Singh M. Modulation of Host Immune Response Is an Alternative Strategy to Combat SARS-CoV-2 Pathogenesis. Front Immunol 2021;12:660632. [PMID: 34305892 DOI: 10.3389/fimmu.2021.660632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Guo W, Pan B, Sakkiah S, Ji Z, Yavas G, Lu Y, Komatsu TE, Lal-Nag M, Tong W, Patterson TA, Hong H. Informing selection of drugs for COVID-19 treatment through adverse events analysis. Sci Rep 2021;11:14022. [PMID: 34234253 DOI: 10.1038/s41598-021-93500-5] [Reference Citation Analysis]
73 Li J, Luo H, Deng G, Chang J, Qiu X, Liu C, Qin B. Multidimensional Evaluation of All-Cause Mortality Risk and Survival Analysis for Hospitalized Patients with COVID-19. Int J Med Sci 2021;18:3140-9. [PMID: 34400884 DOI: 10.7150/ijms.58889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Rai M, Bonde S, Yadav A, Bhowmik A, Rathod S, Ingle P, Gade A. Nanotechnology as a Shield against COVID-19: Current Advancement and Limitations. Viruses 2021;13:1224. [PMID: 34202815 DOI: 10.3390/v13071224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Abdulla ZA, Al-Bashir SM, Al-Salih NS, Aldamen AA, Abdulazeez MZ. A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development. Pathogens 2021;10:788. [PMID: 34206507 DOI: 10.3390/pathogens10070788] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
76 Monzavi SM, Naderi M, Ahmadbeigi N, Kajbafzadeh AM, Muhammadnejad S. An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19. Cell Immunol 2021;367:104398. [PMID: 34217004 DOI: 10.1016/j.cellimm.2021.104398] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Li Z, Wang Z, Dinh PC, Zhu D, Popowski KD, Lutz H, Hu S, Lewis MG, Cook A, Andersen H, Greenhouse J, Pessaint L, Lobo LJ, Cheng K. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. Nat Nanotechnol 2021;16:942-51. [PMID: 34140674 DOI: 10.1038/s41565-021-00923-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
78 Arjmand B, Alavi-Moghadam S, Parhizkar Roudsari P, Rezaei-Tavirani M, Rahim F, Gilany K, Mohamadi-Jahani F, Adibi H, Larijani B. COVID-19 Pathology on Various Organs and Regenerative Medicine and Stem Cell-Based Interventions. Front Cell Dev Biol 2021;9:675310. [PMID: 34195193 DOI: 10.3389/fcell.2021.675310] [Reference Citation Analysis]
79 Danladi J, Sabir H. Innate immunity, inflammation activation and heat-shock protein in COVID-19 pathogenesis. J Neuroimmunol 2021;358:577632. [PMID: 34186336 DOI: 10.1016/j.jneuroim.2021.577632] [Reference Citation Analysis]
80 Bertsimas D, Digalakis Jr V, Jacquillat A, Li ML, Previero A. Where to locate COVID ‐19 mass vaccination facilities? Naval Research Logistics 2022;69:179-200. [DOI: 10.1002/nav.22007] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Gediz Erturk A, Sahin A, Bati Ay E, Pelit E, Bagdatli E, Kulu I, Gul M, Mesci S, Eryilmaz S, Oba Ilter S, Yildirim T. A Multidisciplinary Approach to Coronavirus Disease (COVID-19). Molecules 2021;26:3526. [PMID: 34207756 DOI: 10.3390/molecules26123526] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Sabbatino F, Conti V, Franci G, Sellitto C, Manzo V, Pagliano P, De Bellis E, Masullo A, Salzano FA, Caputo A, Peluso I, Zeppa P, Scognamiglio G, Greco G, Zannella C, Ciccarelli M, Cicala C, Vecchione C, Filippelli A, Pepe S. PD-L1 Dysregulation in COVID-19 Patients. Front Immunol 2021;12:695242. [PMID: 34163490 DOI: 10.3389/fimmu.2021.695242] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
83 Sun Y, Dong W, Tian L, Rao Y, Qin C, Jaramillo SA, Settles EW, Ma S, Zhang J, Yu K, Xu B, Yan J, Ma R, Li Z, Dadwal SS, Barker BM, Keim PS, Feng P, Caligiuri MA, Yu J. Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression. bioRxiv 2021:2021. [PMID: 34127971 DOI: 10.1101/2021.06.07.447286] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
84 Bansal N, Raturi M, Bansal Y. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India. Transfus Clin Biol 2021;28:296-8. [PMID: 34102319 DOI: 10.1016/j.tracli.2021.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
85 Khodajou-Masouleh H, Shahangian SS, Rasti B. Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. Drug Metab Rev 2021;:1-34. [PMID: 33980089 DOI: 10.1080/03602532.2021.1928686] [Reference Citation Analysis]
86 Zhdanov VP. Virology from the perspective of theoretical colloid and interface science. Current Opinion in Colloid & Interface Science 2021;53:101450. [DOI: 10.1016/j.cocis.2021.101450] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
87 Haavik H, Niazi IK, Kumari N, Amjad I, Duehr J, Holt K. The Potential Mechanisms of High-Velocity, Low-Amplitude, Controlled Vertebral Thrusts on Neuroimmune Function: A Narrative Review. Medicina (Kaunas) 2021;57:536. [PMID: 34071880 DOI: 10.3390/medicina57060536] [Reference Citation Analysis]
88 Zhang F, Wang Z, Vijver MG, Peijnenburg WJGM. Probing nano-QSAR to assess the interactions between carbon nanoparticles and a SARS-CoV-2 RNA fragment. Ecotoxicol Environ Saf 2021;219:112357. [PMID: 34044308 DOI: 10.1016/j.ecoenv.2021.112357] [Reference Citation Analysis]
89 Husaini AM, Jan KN, Wani GA. Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management. Heliyon 2021;7:e07068. [PMID: 34007917 DOI: 10.1016/j.heliyon.2021.e07068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Rawat P, Sharma D, Srivastava A, Janakiraman V, Gromiha MM. Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies. Sci Rep 2021;11:10220. [PMID: 33986382 DOI: 10.1038/s41598-021-89621-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Singh B, Mal G, Verma V, Tiwari R, Khan MI, Mohapatra RK, Mitra S, Alyami SA, Emran TB, Dhama K, Moni MA. Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era. Stem Cell Res Ther 2021;12:283. [PMID: 33980321 DOI: 10.1186/s13287-021-02334-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, Ye P, Li H, Yu L, Zhou X, Zhou C, Chen X, Zheng X, Xu K, Cai H, Zheng S, Jiang W, Wu X, Li D, Chen L, Luo Q, Wang Y, Qu J, Li Y, Zheng W, Jiang Y, Tang L, Xiang C, Li L. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med 2021;11:e297. [PMID: 33634996 DOI: 10.1002/ctm2.297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
93 Fernandes T, Garrine C, Ferrão J, Bell V, Varzakas T. Mushroom Nutrition as Preventative Healthcare in Sub-Saharan Africa. Applied Sciences 2021;11:4221. [DOI: 10.3390/app11094221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
94 Gupta A, Pradhan A, Maurya VK, Kumar S, Theengh A, Puri B, Saxena SK. Therapeutic approaches for SARS-CoV-2 infection. Methods 2021:S1046-2023(21)00126-2. [PMID: 33962011 DOI: 10.1016/j.ymeth.2021.04.026] [Reference Citation Analysis]
95 Schuurs ZP, Hammond E, Elli S, Rudd TR, Mycroft-West CJ, Lima MA, Skidmore MA, Karlsson R, Chen YH, Bagdonaite I, Yang Z, Ahmed YA, Richard DJ, Turnbull J, Ferro V, Coombe DR, Gandhi NS. Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. Comput Struct Biotechnol J 2021;19:2806-18. [PMID: 33968333 DOI: 10.1016/j.csbj.2021.05.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
96 Liang C, Hui N, Liu Y, Qiao G, Li J, Tian L, Ju X, Jia M, Liu H, Cao W, Yu P, Li H, Ren X. Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic. Phytomedicine Plus 2021;1:100027. [DOI: 10.1016/j.phyplu.2021.100027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Mba IE, Sharndama HC, Osondu-Chuka GO, Okeke OP. Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update. Infect Dis (Lond) 2021;53:559-80. [PMID: 33905282 DOI: 10.1080/23744235.2021.1916071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Laurini E, Marson D, Aulic S, Fermeglia A, Pricl S. Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence. ACS Nano 2021;15:6929-48. [PMID: 33733740 DOI: 10.1021/acsnano.0c10833] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
99 Chen M, Rosenberg J, Cai X, Hsuan Lee AC, Shi J, Nguyen M, Wignakumar T, Mirle V, Edobor AJ, Fung J, Donington JS, Shanmugarajah K, Lin Y, Chang E, Randall G, Penaloza-MacMaster P, Tian B, Madariaga ML, Huang J. Nanotraps for the containment and clearance of SARS-CoV-2. Matter 2021;4:2059-82. [PMID: 33907732 DOI: 10.1016/j.matt.2021.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
100 Mahalingam S, Peter J, Xu Z, Bordoloi D, Ho M, Kalyanaraman VS, Srinivasan A, Muthumani K. Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. Heliyon 2021;7:e06836. [PMID: 33898857 DOI: 10.1016/j.heliyon.2021.e06836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
101 Korkmaz E, Balmert SC, Sumpter TL, Carey CD, Erdos G, Falo LD Jr. Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev 2021;171:164-86. [PMID: 33539853 DOI: 10.1016/j.addr.2021.01.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
102 Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng 2021. [PMID: 33795852 DOI: 10.1038/s41551-021-00698-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
103 Sheervalilou R, Shirvaliloo M, Sargazi S, Bahari S, Saravani R, Shahraki J, Shirvalilou S, Shahraki O, Nazarlou Z, Shams Z, Ghaznavi H. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment. Blood Purif 2021;:1-14. [PMID: 33789273 DOI: 10.1159/000513164] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Jha N, Jeyaraman M, Rachamalla M, Ojha S, Dua K, Chellappan D, Muthu S, Sharma A, Jha S, Jain R, Jeyaraman N, Gs P, Satyam R, Khan F, Pandey P, Verma N, Singh S, Roychoudhury S, Dholpuria S, Ruokolainen J, Kesari K. Current Understanding of Novel Coronavirus: Molecular Pathogenesis, Diagnosis, and Treatment Approaches. Immuno 2021;1:30-66. [DOI: 10.3390/immuno1010004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
105 Taha MA, Hall CA, Shortess CJ, Rathbone RF, Barham HP. Treatment Protocol for COVID-19 Based on T2R Phenotype. Viruses 2021;13:503. [PMID: 33803811 DOI: 10.3390/v13030503] [Reference Citation Analysis]
106 Attia YA, El-Saadony MT, Swelum AA, Qattan SYA, Al-Qurashi AD, Asiry KA, Shafi ME, Elbestawy AR, Gado AR, Khafaga AF, Hussein EOS, Ba-Awadh H, Tiwari R, Dhama K, Alhussaini B, Alyileili SR, El-Tarabily KA, Abd El-Hack ME. COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact-an updated review. Environ Sci Pollut Res Int 2021;28:22241-64. [PMID: 33733422 DOI: 10.1007/s11356-021-13018-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
107 Luellen E. A Machine Learning Explanation of the Pathogen-Immune Relationship of SARS-CoV-2 (COVID-19), and a Model to Predict Immunity and Therapeutic Opportunity: A Comparative Effectiveness Research Study. JMIRx Med 2020;1:e23582. [PMID: 33711083 DOI: 10.2196/23582] [Reference Citation Analysis]
108 Hossain MK, Hassanzadeganroudsari M, Feehan J, Apostolopoulos V. COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate? Vaccines (Basel) 2021;9:241. [PMID: 33802086 DOI: 10.3390/vaccines9030241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
109 Ashford MB, England RM, Akhtar N. Highway to Success—Developing Advanced Polymer Therapeutics. Adv Therap 2021;4:2000285. [DOI: 10.1002/adtp.202000285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Rashidzadeh H, Danafar H, Rahimi H, Mozafari F, Salehiabar M, Rahmati MA, Rahamooz-Haghighi S, Mousazadeh N, Mohammadi A, Ertas YN, Ramazani A, Huseynova I, Khalilov R, Davaran S, Webster TJ, Kavetskyy T, Eftekhari A, Nosrati H, Mirsaeidi M. Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives. Nanomedicine (Lond) 2021;16:497-516. [PMID: 33683164 DOI: 10.2217/nnm-2020-0441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
111 Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev 2021;170:1-25. [PMID: 33359141 DOI: 10.1016/j.addr.2020.12.011] [Cited by in Crossref: 138] [Cited by in F6Publishing: 105] [Article Influence: 138.0] [Reference Citation Analysis]
112 Bayat M, Asemani Y, Mohammadi MR, Sanaei M, Namvarpour M, Eftekhari R. An overview of some potential immunotherapeutic options against COVID-19. Int Immunopharmacol 2021;95:107516. [PMID: 33765610 DOI: 10.1016/j.intimp.2021.107516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Al-Rabia MW, Alhakamy NA, Ahmed OAA, Eljaaly K, Aloafi AL, Mostafa A, Asfour HZ, Aldarmahi AA, Darwish KM, Ibrahim TS, Fahmy UA. Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2: Antiviral Screening and Molecular Docking Studies. Pharmaceutics 2021;13:307. [PMID: 33652894 DOI: 10.3390/pharmaceutics13030307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Kardani K, Bolhassani A. Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches. PLoS One 2021;16:e0247396. [PMID: 33606823 DOI: 10.1371/journal.pone.0247396] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
115 Amin SA, Banerjee S, Gayen S, Jha T. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors? Eur J Med Chem 2021;215:113294. [PMID: 33618158 DOI: 10.1016/j.ejmech.2021.113294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Lintzmaier Petiz L, Glaser T, Scharfstein J, Ratajczak MZ, Ulrich H. P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inflammation. Stem Cell Rev Rep 2021;17:241-52. [PMID: 33575962 DOI: 10.1007/s12015-021-10129-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
117 Feyaerts D, Hedou J, Gillard J, Chen H, Tsai ES, Peterson LS, Ando K, Manohar M, Do E, Dhondalay GKR, Fitzpatrick J, Artandi M, Chang I, Snow TT, Chinthrajah RS, Warren CM, Wittman R, Meyerowitz JG, Ganio EA, Stelzer IA, Han X, Verdonk F, Gaudilliere DK, Mukherjee N, Tsai AS, Rumer KK, Jiang SJ, Valdes-Ferrer SI, Kelly JD, Furman D, Aghaeepour N, Angst MS, Boyd SD, Pinsky BA, Nolan GP, Nadeau KC, Gaudilliere B, McIlwain DR. Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. bioRxiv 2021:2021. [PMID: 33594362 DOI: 10.1101/2021.02.09.430269] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Generoso JS, Barichello de Quevedo JL, Cattani M, Lodetti BF, Sousa L, Collodel A, Diaz AP, Dal-Pizzol F. Neurobiology of COVID-19: how can the virus affect the brain? Braz J Psychiatry 2021:S1516-44462021005003203. [PMID: 33605367 DOI: 10.1590/1516-4446-2020-1488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
119 Khanmohammadi S, Rezaei N. Role of Toll-like receptors in the pathogenesis of COVID-19. J Med Virol 2021;93:2735-9. [PMID: 33506952 DOI: 10.1002/jmv.26826] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 23.0] [Reference Citation Analysis]
120 Ibrahim Fouad G. A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19). Bull Natl Res Cent 2021;45:36. [PMID: 33564223 DOI: 10.1186/s42269-021-00487-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
121 Machhi J, Shahjin F, Das S, Patel M, Abdelmoaty MM, Cohen JD, Singh PA, Baldi A, Bajwa N, Kumar R, Vora LK, Patel TA, Oleynikov MD, Soni D, Yeapuri P, Mukadam I, Chakraborty R, Saksena CG, Herskovitz J, Hasan M, Oupicky D, Das S, Donnelly RF, Hettie KS, Chang L, Gendelman HE, Kevadiya BD. A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention. J Neuroimmune Pharmacol 2021;16:270-88. [PMID: 33544324 DOI: 10.1007/s11481-020-09981-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
122 Donskyi IS, Nie C, Ludwig K, Trimpert J, Ahmed R, Quaas E, Achazi K, Radnik J, Adeli M, Haag R, Osterrieder K. Graphene Sheets with Defined Dual Functionalities for the Strong SARS-CoV-2 Interactions. Small 2021;17:e2007091. [PMID: 33533178 DOI: 10.1002/smll.202007091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
123 Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, Clemens R. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet 2021;397:682-94. [PMID: 33524311 DOI: 10.1016/S0140-6736(21)00241-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 42.0] [Reference Citation Analysis]
124 Patrick MT, Zhang H, Wasikowski R, Prens EP, Weidinger S, Gudjonsson JE, Elder JT, He K, Tsoi LC. Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol 2021;147:857-869.e7. [PMID: 33485957 DOI: 10.1016/j.jaci.2021.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
125 Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells 2021;10:206. [PMID: 33494237 DOI: 10.3390/cells10020206] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
126 Stephensen CB, Lietz G. Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2.Br J Nutr. 2021;1-10. [PMID: 33468263 DOI: 10.1017/S0007114521000246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
127 Şehirli AÖ, Sayıner S. Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients. Med Hypotheses 2021;147:110504. [PMID: 33485026 DOI: 10.1016/j.mehy.2021.110504] [Reference Citation Analysis]
128 Andryukov BG, Besednova NN, Kuznetsova TA, Fedyanina LN. Laboratory-Based Resources for COVID-19 Diagnostics: Traditional Tools and Novel Technologies. A Perspective of Personalized Medicine. J Pers Med 2021;11:42. [PMID: 33451039 DOI: 10.3390/jpm11010042] [Reference Citation Analysis]
129 Barbosa LC, Gonçalves TL, de Araujo LP, Rosario LVO, Ferrer VP. Endothelial cells and SARS-CoV-2: An intimate relationship. Vascul Pharmacol 2021;137:106829. [PMID: 33422689 DOI: 10.1016/j.vph.2021.106829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
130 Huergo MAC, Thanh NTK. Current advances in the detection of COVID-19 and evaluation of the humoral response. Analyst 2021;146:382-402. [PMID: 33410826 DOI: 10.1039/d0an01686a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
131 Aydogdu MO, Altun E, Chung E, Ren G, Homer-Vanniasinkam S, Chen B, Edirisinghe M. Surface interactions and viability of coronaviruses. J R Soc Interface 2021;18:20200798. [PMID: 33402019 DOI: 10.1098/rsif.2020.0798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
132 Napoli C, Benincasa G, Criscuolo C, Faenza M, Liberato C, Rusciano M. Immune reactivity during COVID-19: Implications for treatment. Immunol Lett 2021;231:28-34. [PMID: 33421440 DOI: 10.1016/j.imlet.2021.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
133 Hamouche W, Bisserier M, Brojakowska A, Eskandari A, Fish K, Goukassian DA, Hadri L. Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. J Mol Cell Cardiol 2021;153:72-85. [PMID: 33373644 DOI: 10.1016/j.yjmcc.2020.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs 2020;12:1854149. [PMID: 33319649 DOI: 10.1080/19420862.2020.1854149] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 21.0] [Reference Citation Analysis]
135 Shah M, Captain J, Vaidya V, Kulkarni A, Valsangkar K, Nair PMK, Ganu G. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study). Int Immunopharmacol 2021;91:107301. [PMID: 33421928 DOI: 10.1016/j.intimp.2020.107301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
136 Kumar V, Doshi KU, Khan WH, Rathore AS. COVID‐19 pandemic: mechanism, diagnosis, and treatment. J Chem Technol Biotechnol 2021;96:299-308. [DOI: 10.1002/jctb.6641] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
137 . Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol 2020;15:963. [PMID: 33247210 DOI: 10.1038/s41565-020-00820-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 23.5] [Reference Citation Analysis]
138 Vivarelli S, Falzone L, Torino F, Scandurra G, Russo G, Bordonaro R, Pappalardo F, Spandidos DA, Raciti G, Libra M. Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review). Int J Oncol 2021;58:145-57. [PMID: 33491759 DOI: 10.3892/ijo.2020.5159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
139 Hsieh KL, Wang Y, Chen L, Zhao Z, Savitz S, Jiang X, Tang J, Kim Y. Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, and Epidemiological Validation. Res Sq 2020:rs. [PMID: 33330858 DOI: 10.21203/rs.3.rs-114758/v1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Al-ahmady ZS, Ali-boucetta H. Nanomedicine & Nanotoxicology Future Could Be Reshaped Post-COVID-19 Pandemic. Front Nanotechnol 2020;2:610465. [DOI: 10.3389/fnano.2020.610465] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Kumar R, Lee MH, Mickael C, Kassa B, Pasha Q, Tuder R, Graham B. Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19. ERJ Open Res 2020;6:00405-2020. [PMID: 33313306 DOI: 10.1183/23120541.00405-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
142 Bonam SR, Kotla NG, Bohara RA, Rochev Y, Webster TJ, Bayry J. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today 2021;36:101051. [PMID: 33519949 DOI: 10.1016/j.nantod.2020.101051] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
143 Jamalipour Soufi G, Iravani S. Potential inhibitors of SARS-CoV-2: recent advances. J Drug Target 2021;29:349-64. [PMID: 33210953 DOI: 10.1080/1061186X.2020.1853736] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Sheek-Hussein M, Abu-Zidan FM. Invited Editorial. COVID-19 Vaccine: Hope and reality. Afr Health Sci 2020;20:1507-9. [PMID: 34394211 DOI: 10.4314/ahs.v20i4.3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
145 Ferreira LLG, Andricopulo AD. Medicamentos e tratamentos para a Covid-19. Estud av 2020;34:7-27. [DOI: 10.1590/s0103-4014.2020.34100.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Steckelings UM, Sumners C. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. Clin Sci (Lond) 2020;134:2987-3006. [PMID: 33210709 DOI: 10.1042/CS20200922] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
147 Santopolo S, Riccio A, Santoro MG. The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. Biochem Biophys Res Commun 2021;538:80-7. [PMID: 33303190 DOI: 10.1016/j.bbrc.2020.10.080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Sharma P, Pandey AK, Bhattacharyya DK. Determining crucial genes associated with COVID-19 based on COPD Findings✶,✶✶. Comput Biol Med 2021;128:104126. [PMID: 33260035 DOI: 10.1016/j.compbiomed.2020.104126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 Karabasz A, Bzowska M, Szczepanowicz K. Biomedical Applications of Multifunctional Polymeric Nanocarriers: A Review of Current Literature. Int J Nanomedicine 2020;15:8673-96. [PMID: 33192061 DOI: 10.2147/IJN.S231477] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
150 Hussen J, Kandeel M, Hemida MG, Al-Mubarak AIA. Antibody-Based Immunotherapeutic Strategies for COVID-19. Pathogens. 2020;9. [PMID: 33167401 DOI: 10.3390/pathogens9110917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
151 Vadlamani BS, Uppal T, Verma SC, Misra M. Functionalized TiO2 Nanotube-Based Electrochemical Biosensor for Rapid Detection of SARS-CoV-2. Sensors (Basel) 2020;20:E5871. [PMID: 33080785 DOI: 10.3390/s20205871] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 19.0] [Reference Citation Analysis]
152 Gao Q, Liu J, Mu Z, Yan X, Shah JN, Jiao F. Clinical Profile of COVID-19 in Children and Research Progress on Angiotensin-converting Enzyme 2: A Mini-review. JNMA J Nepal Med Assoc 2020;58:813-9. [PMID: 34504360 DOI: 10.31729/jnma.5436] [Reference Citation Analysis]
153 Garg P, Sangam S, Kochhar D, Pahari S, Kar C, Mukherjee M. Exploring the role of triazole functionalized heteroatom co-doped carbon quantum dots against human coronaviruses. Nano Today 2020;35:101001. [PMID: 33052202 DOI: 10.1016/j.nantod.2020.101001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
154 Esmaeilzadeh A, Elahi R. Immunobiology and immunotherapy of COVID-19: A clinically updated overview. J Cell Physiol 2021;236:2519-43. [PMID: 33022076 DOI: 10.1002/jcp.30076] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
155 Mélo Silva Júnior ML, Souza LMA, Dutra REMC, Valente RGM, Melo TS. Review on therapeutic targets for COVID-19: insights from cytokine storm. Postgrad Med J 2021;97:391-8. [PMID: 33008960 DOI: 10.1136/postgradmedj-2020-138791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
156 Renu K, Subramaniam MD, Chakraborty R, Myakala H, Iyer M, Bharathi G, Siva K, Vellingiri B, Valsala Gopalakrishnan A. The role of Interleukin-4 in COVID-19 associated male infertility - A hypothesis. J Reprod Immunol 2020;142:103213. [PMID: 33080435 DOI: 10.1016/j.jri.2020.103213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
157 Brooke GN, Prischi F. Structural and functional modelling of SARS-CoV-2 entry in animal models. Sci Rep 2020;10:15917. [PMID: 32985513 DOI: 10.1038/s41598-020-72528-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
158 Lee DYW, Li QY, Liu J, Efferth T. Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. Phytomedicine 2021;80:153337. [PMID: 33221457 DOI: 10.1016/j.phymed.2020.153337] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
159 Khatri I, Staal FJT, van Dongen JJM. Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective. Front Immunol 2020;11:570018. [PMID: 33042151 DOI: 10.3389/fimmu.2020.570018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
160 Thomford NE, Yahaya ES, Ekor M, Awortwe C. Turning Up the Volume for Precision Herbal Medicine in Africa in an Era of COVID-19 and Planetary Biodiversity Loss. OMICS 2020;24:682-4. [PMID: 32833598 DOI: 10.1089/omi.2020.0150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Iravani S. Nano- and biosensors for the detection of SARS-CoV-2: challenges and opportunities. Mater Adv 2020;1:3092-103. [DOI: 10.1039/d0ma00702a] [Cited by in Crossref: 17] [Article Influence: 8.5] [Reference Citation Analysis]
162 [DOI: 10.1101/2020.11.12.380709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
163 [DOI: 10.1101/2020.12.03.20243709] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
164 [DOI: 10.1101/2021.02.14.431117] [Cited by in Crossref: 37] [Cited by in F6Publishing: 6] [Reference Citation Analysis]